WO2025022317 - BLARCAMESINE CO-CRYSTALS FOR THE MANUFACTURE OF PHARMACEUTICAL DOSAGE FORM
National phase entry is expected:
Publication Number
WO/2025/022317
Publication Date
30.01.2025
International Application No.
PCT/IB2024/057148
International Filing Date
23.07.2024
Title **
[English]
BLARCAMESINE CO-CRYSTALS FOR THE MANUFACTURE OF PHARMACEUTICAL DOSAGE FORM
[French]
CO-CRISTAUX DE BLARCAMÉSINE POUR LA FABRICATION D'UNE FORME POSOLOGIQUE PHARMACEUTIQUE
Applicants **
EGIS GYOGYSZERGYAR ZRT.
Inventors
SZOKOL, Zsuzsanna
NAGY, Tamas
DANCSO, Andras Balazs
VIRAG, Attila
NEMETHNE CSILLAG, Regina
LOZSI, Karoly
VOLK, Balazs
SZLAVIK, Laszlo
Priority Data
18/225,925
25.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2172 | |
| EPO | Filing, Examination, Granting | 9467 | |
| Japan | Filing, Examination, Granting | 2243 | |
| South Korea | Filing, Examination, Granting | 2166 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
22,588
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
)-(+)-blarcamesine hydrochloride of formula (2c), processes for preparation thereof and pharmaceutical preparation thereof and methods of treating neurodegenerative, neurodeveiopmental diseases such as Alzheimer's disease, Parkinson's disease dementia and/or Rett syndrome.[French]
de chlorhydrate de (R)-(+)-blarcamésine de formule (2c), leurs procédés de préparation et leur préparation pharmaceutique et des méthodes de traitement de maladies neurodégénératives, neurodéveloppementales telles que la maladie d'Alzheimer, la démence de Parkinson et/ou le syndrome de Rett.